P15INK4b Gene Methylation and Myelodysplastic Syndromes

Leukemia and Lymphoma

Volumn 35, Issue 42130, 1999, Pages 437-443

  Quesnel, Bruno ^a,b   Fenaux, Pierre ^a,b  

^a INSERM   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cell cycle; MDS; methylation; P15INK4b; TGF

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; PROTEIN P15; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC ANTIMETABOLITE; CARRIER PROTEIN; CDKN2B PROTEIN, HUMAN; CDKN2B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DRUG DERIVATIVE; PROTEIN P16INK4A; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; DNA METHYLATION; HUMAN; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; ACUTE DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL; CELL CYCLE; CELL DIFFERENTIATION; CELL TRANSFORMATION; CHROMOSOME 9; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEMATOPOIESIS; METABOLISM; MOUSE; MYELOID LEUKEMIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; PRECANCER; REVIEW; TUMOR SUPPRESSOR GENE;

ACUTE DISEASE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 9; CLINICAL TRIALS, PHASE II; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; DNA METHYLATION; GENES, P16; GENES, TUMOR SUPPRESSOR; HEMATOPOIESIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MICE; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

EID: 0033233233     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428199909169608     Document Type: Article

References (68)

1. Jones P. A. DNA methylation errors and cancer. Cancer Res 1996; 56: 2463 – 2467
2. Razin A., Shemer R. DNA methylation in early development. Hum Mol Genet. 1995; 1995: 1751 – 1755, Spec No
3. Razin A., Kafri T. DNA methylation from embryo to adult. Prog Nucleic Acid Res Mol Biol 1994; 48: 53 – 81
4. Razin A., Cedar H. DNA methylation and genomic imprinting. Cell 1994; 77: 473 – 476
5. Razin A. CpG methylation. chromatin structure and gene silencing-a three-way connection. Embo J 1998; 17: 4905 – 4908
6. Pazin M. J., Kadonaga J. T. What's up and down with histone deacetylation and transcription?. Cell 1997; 89: 325 – 328
7. Pikaart M. J., Recillas-Targa F., Felsenfeld G. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 1998; 12: 2852 – 2862
8. Jones P. L., Veenstra G. J., Wade P. A., Vermaak D., Kass S. U., Landsberger N., Strouboulis J., Wolffe A. P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187 – 191
9. Cameron E. E., Bachman K. E., Myohanen S., Herman J. G., Baylin S. B. Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer. Nat Genet 1999; 21: 103 – 107
10. Rougier N., Bourc'his D., Gomes D. M., Niveleau A., Plachot M., Paldi A., Viegas-Pequignot E. Chromosome methylation patterns during mammalian preimplantation development. Genes Dev 1998; 12: 2108 – 2113
11. Mostoslavsky R., Singh N., Kirillov A., Pelanda R., Cedar H., Chess A., Bergman Y. Kappa chain monoallelic demethylation and the establishment of allelic exclusion. Genes Dev 1998; 12: 1801 – 1811
12. Saggioro D., Forino M., Chieco-Bianchi L. Transcriptional block of HTLV-I LTR by sequence-specific methylation. Virology 1991; 182: 68 – 75
13. Robertson K. D., Ambinder R. F. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood 1997; 90: 4480 – 4484
14. Robertson K. D., Manns A., Swinnen L. J., Zong J. C., Gulley M. L., Ambinder R. F. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood 1996; 88: 3129 – 3136
15. Jones P. A., Laird P. W. Cancer epigenetics comes of age [In Process Citation]. Nat Genet 1999; 21: 163 – 167
16. Lengauer C., Kinzler K. W., Vogelslein B. DNA methylation and genetic instability in colorectal cancer cells [see comments]. Proc Natl Acad Sci USA 1997; 94: 2545 – 2550
17. Ramchandani S., MacLeod A. R., Pinard M., von Hofe E., Szyf M. Inhibition of tumorigenesis by a cytosine-DNA. methyltransferase. antisense oligodeoxynu-cleotide. Proc Natl Acad Sci U S A 1997; 94: 684 – 689
18. Jones P. A., Gonzalgo M. L. Altered DNA methylation and genome instability: a new pathway to cancer? [comment]. Proc Natl Acad Sci U S A 1997; 94: 2103 – 2105
19. Baylin S. B., Herman J. G., Graff J. R., Vertino P. M., Issa J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141 – 196
20. Drexler H. G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16. p18 and p19 in human leukcmia-lymphoma cells. Leukemia 1998; 12: 845 – 859
21. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers [see comments]. Nat Med. 1995; 1: 686 – 692
22. Martinez-Delgado B., Fernandez-Piqueras J., Garcia M. J., Arranz E., Gallego J., Rivas C., Robledo M., Benitez J. Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997; 11: 128 – 425
23. Herman J. G., Civin C. I., Issa J. P., Collector M. I., Sharkis S. J., Baylin S. B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837 – 841
24. Malumbres M., Péd C. I., Santos J., Meléndez B., Mangues R., Serrano M., Pellicer A., Fernández-Piqueras J. Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene 1997; 14: 1361 – 1370
25. Tulchinsky E., Grigorian M., Tkatch T., Georgiev G., Lukanidin E. Transcriptional regulation of the mtsl gene in human lymphoma cells: the role of DNA-methylation. Biochim Biophys Acta 1995; 1261: 243 – 248
26. Klangby U., Okan I., Magnusson K. P., Wendland M., Lind P., Wiman K. G. P16/ink4a and p15/ink4b gene methylation and absence of p 16/ink4a mRna and protein expression in Burkitt's lymphoma. Blood 1998; 91: 1680 – 1687
27. Martinez-Delgado B., Robledo M., Arranz E., Osorio A., Garcia M. J., Echezarreta G., Rivas C., Benitez J. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia 1998; 12: 937 – 941
28. Zhang S. J., Endo S., Ichikawa T., Washiyama K., Kumanishi T. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res 1998; 58: 1231 – 1237
29. Villuendas R., Sanchez-Beato M., Martinez J. C., Saez A. I., Martinez-Delgado B., Garcia J. F., Mateo M. S., Sanchez-Verde L., Benitez J., Martinez P., Piris M. A. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 1998; 153: 887 – 897
30. Tasaka T., Berenson J., Vescio R., Hirama T., Miller C. W., Nagai M., Takahara J., Koeffler H. P. Analysis of the p16(INK4A). p15(INK4B) and p18(INK4C) genes in multiple myeloma. British Journal of Haematology 1997; 96: 98 – 102
31. Ng M. H., Chung Y. F., Lo K. W., Wickham N. W., Lee J. C., Huang D. P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997; 89: 2500 – 2506
32. Wong I. H., Ng M. H., Lee J. C., Lo K. W., Chung Y. F., Huang D. P. Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation [In Process Citation]. Br J Haematol 1998; 103: 168 – 175
33. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525 – 4530
34. Herman J. G., Jen J., Merlo A., Baylin S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996; 56: 722 – 727
35. Jonveaux P., Fenaux P., Quiquandon I., Pignon J. M., Laï J. M., Loucheux-Lefebvre M. H., Goossens M., Bauters F., Berger R. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene. 1991; 6: 2243 – 2247
36. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148 – 3157
37. Quesnel B., Preudhomme C., Philippe N., Vanrumbeke M., Dervite I., Lai J. L., Bauters F., Wattel E., Fenaux P. P16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995; 85: 657 – 663
38. Quesnel B., Preudhomme C., Fenaux P. P16Ink4A gene and hematological malignancies. Leuk Lymphoma 1996; 22: 11 – 24
39. Nakamaki T., Bartram C., Seriu T., Kahan J., Fukuchi K., Tsuruoka N., Janssen J. W., Miller C. W., Koeffler H. P. Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16. p18 and p19 in the myelodysplastic syndromes. Leuk Res 1997; 21: 235 – 240
40. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., Vanrumbeke M., Fenaux P. Methylation of the p15 gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985 – 2990
41. Uchida T., Kinoshita T., Nagai H., Nakahara Y., Saito H., Hotta T., Murate T. Hypermethylation of the p15(INK4B) gene in myelodysplastic syndromes. Blood 1997; 90: 1403 – 1409
42. Uchida T., Ohashi H., Kinoshita T., Sailo H., Taguchi R., Hotta T., Murate T. Hypermethylation of p15(INK4B) gene in a patient with acute myelogenous leukemia evolved from paroxysmal nocturnal hemoglobinuria [letter]. Blood 1998; 92: 2981 – 2983
43. Whitman M. Smads and early developmental signaling by the TG Fbeta superfamily. Genes Dev 1998; 12: 2445 – 2462
44. Ramsfjell V., Borge O. J., Cui L., Jacobsen S. E. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3. and inhibitory effects of TGF-beta and TNF-alpha. J Immunol 1997; 158: 5169 – 5177
45. Bonnet D., Lemoine F. M., Najman A., Guigon M. Comparison of the inhibitory effect of AcSDKP. TNF-alpha. TGF-beta, and MIP-1 alpha on marrow-purified CD34+ progenitors. Exp Hematol 1995; 23: 551 – 556
46. Lardon F., Snoeck H. W., Nijs G., Lenjou M., Peetermans M. E., Rodrigus I., Berneman Z. N., Van Bockstaele D. R. Transforming growth factor-beta regulates the cell cycle status of interleukin-3 (IL-3) plus IL-1, stem cell factor, or IL-6 stimulated CD34+ human hematopoietic progenitor cells through different cell kinetic mechanisms depending on the applied stimulus. Exp Hematol 1994; 22: 903 – 909
47. Mayani H., Little M. T., Dragowska W., Thornbury G., Lansdorp P. M. Differential effects of the hematopoietic inhibitors MIP- 1 alpha, TGF-beta, and TNF-alpha on cytokine-induced proliferation of subpopulations of CD34+ cells purified from cord blood and fetal liver. Exp Hematol 1995; 23: 422 – 427
48. Van Ranst P. C., Snoeck H. W., Lardon F., Lenjou M., Nijs G., Weekx S. F., Rodrigus I., Berneman Z. N., Van Bockstaele D. R. TGF-beta and MIP-1 alpha exert their main inhibitory activity on very primitive CD34+2CD38-cells but show opposite effects on more mature CD34+CD38+ human hematopoietic progenitors. Exp Hematol 1996; 24: 1509 – 1515
49. Imbert A. M., Bagnis C., Galindo R., Chabannon C., Mannoni P. A neutralizing anti-TGF-beta 1 antibody promotes proliferation of CD34+Thy-1 + peripheral blood progenitors and increases the number of transduced progenitors. Exp Hematol 1998; 26: 374 – 381
50. Bruno E., Horrigan S. K., Van Den Berg D., Rozler E., Fitting P. R., Moss S. T., Westbrook C., Hoffman R. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 1998; 91: 1917 – 1923
51. Li M. L., Cardoso A. A., Sansilvestri P., Hatzfeld A., Brown E. L., Sookdeo H., Levesque J. P., Clark S. C., Hatzfeld J. Additive effects of steel factor and antisense TGF-beta 1 oligodeoxynucleotide on CD34+ hematopoietic progenitor cells. Leukemia 1994; 8: 441 – 445
52. Cardoso A. A., Li M. L., Batard P., Hatzfeld A., Brown E. L., Levesque J. P., Sookdeo H., Panterne B., Sansilvestri P., Clark S. C., et al. Release from quiescence of CD34+ CD38- human umbilical cord blood cells reveals their potentiality to engraft adults. Proc Natl Acad Sci U S A 1993; 90: 8707 – 8711
53. Drexler H. G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588 – 599
54. Sott C., Dorner B., Karawajew L., Herrmann F., Brach M. A. Transforming growth factor-beta relieves stem cell factor- induced proliferation of myelogenous leukemia cells through inhibition of binding of the transcription factor NF-jun. Blood 1994; 84: 1950 – 1959
55. Murohashi I., Endho K., Nishida S., Yoshida S., Jinnai I., Bessho M., Hirashima K. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation. Exp Hematol 1995; 23: 970 – 977
56. Kurokawa M., Mitani K., Imai Y., Ogawa S., Yazaki Y., Hirai H. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood 1998; 92: 4003 – 40012
57. Sasaki H., Matsuda M., Lu Y., Ikuta K., Matsuyama S., Hirabayashi Y., Mitsui H., Matsumura T., Muramatsu M., Tsukada T., Aizawa S., Inoue. A fraction unresponsive to growth inhibition by TGF-beta among the high-proliferative potential progenitor cells in bone marrow of p53-deficient mice. Leukemia 1997; 11: 239 – 244
58. Drexler H. G., Meyer C., Zaborski M., Uphoff C. C., Quentmeier H. Growth-inhibitory effects of transforming growth factor-beta 1 on myeloid leukemia cell lines. Leuk Res 1998; 22: 927 – 938
59. Cá J, Zentella A., Massagué J. Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol 1995; 15: 1573 – 1581
60. Guo Y., Kyprianou N. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta 1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 1998; 9: 185 – 193
61. Wieser R., Gruber B., Rieder H., Fonatsch C. Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia. Leukemia 1998; 12: 1114 – 1118
62. Grady W. M., Rajput A., Myeroff L., Liu D. F., Kwon K., Willis J., Markowitz S. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998; 58: 3101 – 3104
63. Zagonel V., Lo Re G., Marotta G., Babare R., Sardeo G., Gattei V., De Angelis V., Monfardini S., Pinto A. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993; 7 (Suppl 1) 30 – 35
64. Pinto A., Zagonel V. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7 (Suppl 1) 51 – 60
65. Cheson B. D. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res. 1998; 22 (Suppl 1) S17 – 21
66. Wijermans P. W., Krulder J. W., Huijgens P. C., Neve P. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11 (Suppl 1) S19 – 23
67. Daskalis M., Nguyen T. T., Wijermans P., Jones P. A., M. L. Frequent hypermethylation of p15INK4b in patients with myelodysplastic syndromes is decreased following treatment with 5-Aza-2'deoxycytidine (decitabine). American Society of Hematology, Fortieth Annual meeting, Blood. Miami 1998; Vol. 92, p. Abstract 2937
68. Yeager T. R., DeVries S., Jarrard D. F., Kao C., Nakada S. Y., Moon T. D., Bruskewitz R., Stadler W. M., Meisner L. F., Gilchrist K. W., Newton M. A., Waldman F. M., Reznikoff C. A. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev 1998; 12: 163 – 174